Browsing: Patients
The PrE0405 phase 2 trial met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients…
The combination of the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing spleen enlargement…
Patients with low-risk ductal carcinoma in situ (DCIS) who omitted adjuvant radiotherapy after breast-conserving surgery had comparable five-year outcomes to…
PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), announced today that it has…